Drug Name | Company | Therapy Area | Year |
Ofatumumab (OMB-157; Kesimpta) | Novartis International AG | Neurology/psychiatric | 2020 |
Ozanimod (RPC-1063; Zeposia) | Celgene Corporation | Neurology/psychiatric | 2020 |
Rimegepant (BHV-3000; Nurtec) | Biohaven Pharmaceutical Holding Co. Ltd. | Neurology/psychiatric | 2020 |
Sacituzumab govitecan (IMMU-132) | Immunomedics Inc., Medicine Inc. | Oncology | 2020 |
Semaglutide (Rybelsus) | Novo Nordisk A/S | Endocrinology/metabolic disease | 2020 |
Trastuzumab deruxtecan (DS-8201a; Enhertu) | AstraZeneca plc, Daiichi Sankyo Co. Ltd. | Oncology | 2020 |
Vadadustat | Akebia Therapeutics Inc., Mitsubishi Tanabe Pharma America Inc., Otsuka Pharmaceutical | Chronic disease complication | 2020 |
Valoctocogene roxaparvovec (BMN-270; Valrox) | Biomarin Pharmaceutical Inc. | Genetic disorder | 2020 |
Betibeglogene darolentivec (LentiGlobin) | Bluebird Bio Inc. | Genetic disorder | 2019 |
Onasemnogene abeparvovec (AVXS-101; Zolgensma) | AveXis | Genetic disorder | 2019 |
Palforzia (AR101; Aerumab) | Aimmune Therapeutics | Excessive immune response/autoimmunity | 2019 |
Ravulizumab (ALXN-1210; Ultomiris) | Alexion Pharmaceuticals Inc. | Excessive immune response/autoimmunity, Genetic disorder | 2019 |
Risankizumab (BI-655066; ABBV-066; Skyrizi) | AbbVie Inc., Boehringer Ingelheim | Excessive immune response/autoimmunity | 2019 |
Roxadustat (FG-4592; AZD-9941; ASP-1517; Ai Rui Zhuo) | Astellas Pharma Inc., AstraZeneca plc, FibroGen | Chronic disease complication | 2019 |
Upadacitinib (ABT-494; Rinvoq) | AbbVie Inc. | Excessive immune response/autoimmunity | 2019 |
Apalutamide (Erleada) | Johnson & Johnson | Oncology | 2018 |
Buprenorphine (Sublocade) | Indivior plc | Addiction | 2018 |
Cannabidiol (Epidiolex) | GW Pharmaceuticals plc | Neurology/psychiatric | 2018 |
Elagolix (Orilissa) | AbbVie Inc. | Reproductive health | 2018 |
Emicizumab (Hemlibra) | Chugai, Roche | Hematology | 2018 |
Erenumab (Aimovig) | Amgen, Novartis International AG | Neurology/psychiatric | 2018 |
Ertugliflozin (Steglatro) | Merck & Co., Pfizer Inc. | Endocrinology/metabolic disease | 2018 |
Lanadelumab (Takhzyro) | Shire | Genetic disorder | 2018 |
Patisiran (Onpattro) | Alnylam Pharmaceuticals Inc., Sanofi Genzyme | Genetic disorder | 2018 |
Shingrix vaccine | GlaxoSmithKline plc | Infectious disease | 2018 |
Tenofovir alafenamide plus emtricitabine plus bictegravir (Biktarvy) | Gilead Sciences Inc. | Infectious disease | 2018 |
Avelumab (Bavencio) | Merck Serono, Pfizer Inc. | Oncology | 2017 |
Axicabtagene ciloleucel (KTE-C19; Yescarta) | Kite Pharma | Oncology | 2017 |
Baricitinib (Olumiant) | Eli Lilly and Co., Incyte Corp. | Excessive immune response/autoimmunity | 2017 |
Dupilumab (Dupixent) | Regeneron Pharmaceuticals Inc., Sanofi SA | Excessive immune response/autoimmunity | 2017 |
Durvalumab (Imfinzi) | AstraZeneca plc | Oncology | 2017 |
Niraparib (Zejula) | Tesaro | Oncology | 2017 |
Ocrelizumab (Ocrevus) | Roche | Neurology/psychiatric | 2017 |
Ribociclib (LEE-011; Kisqali) | Novartis International AG | Oncology | 2017 |
Semaglutide (Ozempic) | Novo Nordisk A/S | Endocrinology/metabolic disease | 2017 |
Emtricitabine plus tenofovir alafenamide (Descovy) | Gilead Sciences Inc., Japan Tobacco | Infectious disease | 2016 |
Grazoprevir plus elbasvir (MK-5172A) | Merck & Co. | Infectious disease | 2016 |
Obeticholic acid (Ocaliva) | Intercept Pharmaceuticals, Sumitomo Dainippon Pharma | Hepatology | 2016 |
Pimavanserin (Nuplazid) | ACADIA Pharmaceuticals | Neurology/psychiatric | 2016 |
Tenofovir alafenamide plus emtricitabine plus rilpivirine (Odefsey) | Gilead Sciences Inc., Janssen R&D | Infectious disease | 2016 |
Selexipag (Uptravi) | Actelion, Nippon Shinyaku Co. | Cardiovascular disease | 2016 |
Venetoclax (Venclexta; Venclyxto) | AbbVie Inc. | Oncology | 2016 |
Alirocumab (Praluent) | Regeneron Pharmaceuticals Inc., Sanofi SA | Cardiovascular disease | 2015 |
Brexpiprazole (Rexulti) | Lundbeck, Otsuka Pharmaceutical | Neurology/psychiatric | 2015 |
Evolocumab (Repatha) | Amgen, Astellas Pharma Inc. | Cardiovascular disease | 2015 |
Gardasil 9 vaccine | Merck & Co. | Infectious disease | 2015 |
Insulin glargine (Toujeo) | Sanofi SA | Endocrinology/metabolic disease | 2015 |
Lumacaftor plus ivacaftor (Orkambi) | Vertex Pharmaceuticals Inc. | Respiratory disease | 2015 |
Nivolumab (Opdivo) | Bristol-Myers Squibb Co. | Oncology | 2015 |
Palbociclib (Ibrance) | Pfizer Inc. | Oncology | 2015 |
Access global intelligence, advanced analytics and global experts from Clarivate.